March 17, 2016
Knoxville, TN, UNITED STATES, March 17, 2016– ABT Molecular Imaging has partnered with a world renowned oncology group to install the BG-75 Biomarker Generator System in Cyprus. The BG-75 integrates a compact cyclotron, micro-chemistry, and automated quality control, to provide on-demand F-18 FDG production in one seamless solution to support the implementation of PET/CT
The BG-75 will be installed in a new, state-of-the-art Oncology Centre in Limassol, Cyprus, which will provide state of the art oncology services using cutting-edge technology and highly-qualified staff.
“We are very proud to be a part of this new, world-class oncology center”, said Peter Kingma, President and CEO of ABT Molecular Imaging. “The BG-75 Biomarker Generator made it feasible for this innovative group to implement PET/CT by reducing the infrastructure, capital, and operating budgets required with conventional cyclotron solutions.” Professor Nikos Zamboglou, Director for the new Oncology Centre, stated: “After careful analysis, we determined that the ABT BG-75 was ideally suited for our new center, and we are looking forward to being the first to bring Molecular Imaging capabilities to Cyprus.”
About ABT Molecular Imaging, Inc: ABT Molecular Imaging is a medical imaging company marketing the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry. ABT’s investor partners include Intersouth Partners, River Cities Capital and two TNInvestco Funds, Council & Enhanced Tennessee Fund and Limestone Fund.
For all media enquires please contact:
Rick Rippin, Director of Sales
Telephone: +1 407-615-0776 / Email: email@example.com
The Company is headquartered in Knoxville, Tennessee. For more information visit www.abt-mi.com